Nakamichi Kosuke, Yoshino Tetsuhiro, Akiyama Masahiro, Jibiki Aya, Yokoyama Yuta, Kawazoe Hitoshi, Suzuki Sayo, Watanabe Kenji, Kim Yun-Gi, Nakamura Tomonori
Division of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, 1-5-30 Shibakoen, Minato-ku, Tokyo, 105-8512, Japan.
Center for Kampo Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
J Nat Med. 2025 Jun 25. doi: 10.1007/s11418-025-01917-3.
Inhibiting body fat accumulation is important for the prevention of obesity. In Japan, three Kampo medicines are commonly used to treat obesity: bofutsushosan, boiogito, and daisaikoto. To compare the influences of these Kampo medicines on the intestinal microbiota, it is necessary to conduct a simultaneous investigation using the same mouse model under the same experimental conditions. C57BL/6J mice were divided into five groups: normal chow (NC), high-fat diet (HFD), HFD + 3% bofutsushosan extract (BTS), HFD + 3% boiogito extract (BOT), and HFD + 3% daisaikoto extract (DST). Epididymal white adipose tissue (WAT) weight, mesenteric WAT weight, serum triglyceride levels, and serum total cholesterol levels were measured. Additionally, total bacteria, alpha diversity, beta diversity, and bacterial composition in stool samples were measured. Body weight and epididymal WAT weight gain were significantly inhibited in the BTS-treated group and DST-treated group, but not in the BOT-treated group, compared with the HFD control group. Additionally, serum total cholesterol levels were significantly lower in the DST-treated group than in the HFD group. Specific intestinal bacteria, Clostridium sensu stricto 1, Erysipelatoclostridium, Roseburia, and the Lachnospiraceae NK4A136 group, were significantly changed in the Kampo-treated groups compared with the HFD group, and each of them was correlated with body weight gain, body fat rate, epididymal WAT weight, or mesenteric WAT weight. Our simultaneous investigation of BTS, BOT, and DST under the same conditions clearly demonstrated different changes in the intestinal microbiota and different effects on fat accumulation as well as their association among the three Kampo medicines.
抑制体脂积累对预防肥胖至关重要。在日本，三种汉方药常用于治疗肥胖：防风通圣散、补中益气汤和大柴胡汤。为了比较这些汉方药对肠道微生物群的影响，有必要在相同的实验条件下使用相同的小鼠模型进行同步研究。将C57BL/6J小鼠分为五组：正常饲料（NC）组、高脂饮食（HFD）组、HFD + 3%防风通圣散提取物（BTS）组、HFD + 3%补中益气汤提取物（BOT）组和HFD + 3%大柴胡汤提取物（DST）组。测量附睾白色脂肪组织（WAT）重量、肠系膜WAT重量、血清甘油三酯水平和血清总胆固醇水平。此外，还测量了粪便样本中的总细菌、α多样性、β多样性和细菌组成。与HFD对照组相比，BTS治疗组和DST治疗组的体重和附睾WAT重量增加受到显著抑制，但BOT治疗组未受到抑制。此外，DST治疗组的血清总胆固醇水平显著低于HFD组。与HFD组相比，汉方药治疗组中特定的肠道细菌，即严格意义上的梭菌属1、丹毒丝菌属、罗斯氏菌属和毛螺菌科NK4A136组发生了显著变化，并且它们中的每一种都与体重增加、体脂率、附睾WAT重量或肠系膜WAT重量相关。我们在相同条件下对BTS、BOT和DST进行的同步研究清楚地表明了三种汉方药在肠道微生物群方面的不同变化、对脂肪积累的不同影响以及它们之间的关联。
